ArticleCell reports. Medicine2025
Tumor-specific but immunosuppressive CD39
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CD39 on CD8European journal of immunology · 2026Review
- Article
- A Case of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Achieving Pathologic Complete Response Following Combination Therapy With Lenvatinib and Pembrolizumab.IJU case reports · 2026Article
- Crotonylation and the Risk of Head and Neck Cancer: Insights from a Two-Sample Mendelian Randomization Study.International dental journal · 2026Article
- Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Yong Joon LeeDepartment of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Seung Hyuck JeonGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Jin Hee YeoDepartment of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea; Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
Sun-Ju ByeonDepartment of Pathology, Yuseong Sun Hospital, Daejeon, Republic of Korea.
Jae Hyung JungDepartment of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Heejin NamGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Minwoo JeonDepartment of Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Eui-Soon KimGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Jeon Yeob JangDepartment of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea.
Chul-Ho KimDepartment of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea.
Kee Yang ChungDepartment of Dermatology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jung Yun LeeDepartment of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Shin HwangDepartment of Surgery, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jee Ye KimDepartment of Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Seung-Il KimDepartment of Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jae-Ho CheongDepartment of Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chang Gon KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sang Joon ShinDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Su-Hyung ParkGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Minsun JungDepartment of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jjunglammy@yuhs.ac.
Minyong KangDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Translational Genomics Center, Samsung Medical Center, Seoul, Republic of Korea. Electronic address: dr.minyong.kang@gmail.com.
Seong Il SeoDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: siseo@skku.edu.
Eui-Cheol ShinGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. Electronic address: ecshin@kaist.ac.kr.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD39
Indexed as
Antigens, CDApyraseCarcinoma, Renal CellCD8-Positive T-LymphocytesKidney NeoplasmsAnimalsFemaleHumansLymphocytes, Tumor-InfiltratingMalePrognosisReceptors, Antigen, T-CellVon Hippel-Lindau Tumor Suppressor ProteinAntigens, CDApyraseCD39 antigenENTPD1 protein, humanReceptors, Antigen, T-CellVon Hippel-Lindau Tumor Suppressor Proteinadenosine pathwayanti-PD-1 therapyCD39(+)CD8(+) T cellsclear cell renal cell carcinomahypoxiaimmunosuppressive activityparadoxical prognosistumor antigen specificitytumor microenvironment
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.